WO1993020075A1 - N5-desazapterines substituees en position 8, utilisees comme antifolates - Google Patents
N5-desazapterines substituees en position 8, utilisees comme antifolates Download PDFInfo
- Publication number
- WO1993020075A1 WO1993020075A1 PCT/AU1993/000138 AU9300138W WO9320075A1 WO 1993020075 A1 WO1993020075 A1 WO 1993020075A1 AU 9300138 W AU9300138 W AU 9300138W WO 9320075 A1 WO9320075 A1 WO 9320075A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- compounds
- bind
- binding
- dhfr
- Prior art date
Links
- 230000003432 anti-folate effect Effects 0.000 title description 5
- 229940127074 antifolate Drugs 0.000 title description 5
- 239000004052 folic acid antagonist Substances 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 90
- 238000000034 method Methods 0.000 claims abstract description 63
- -1 hydroxy, thio Chemical group 0.000 claims abstract description 30
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 18
- 229910052736 halogen Chemical group 0.000 claims abstract description 13
- 150000002367 halogens Chemical group 0.000 claims abstract description 13
- 150000002148 esters Chemical class 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 7
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 7
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical group NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 6
- 239000001257 hydrogen Substances 0.000 claims abstract description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 5
- 238000000329 molecular dynamics simulation Methods 0.000 claims description 29
- 230000008859 change Effects 0.000 claims description 17
- 238000006243 chemical reaction Methods 0.000 claims description 16
- 150000001728 carbonyl compounds Chemical class 0.000 claims description 14
- 238000007614 solvation Methods 0.000 claims description 13
- 125000001424 substituent group Chemical group 0.000 claims description 13
- 238000006467 substitution reaction Methods 0.000 claims description 13
- HNXQXTQTPAJEJL-UHFFFAOYSA-N 2-aminopteridin-4-ol Chemical group C1=CN=C2NC(N)=NC(=O)C2=N1 HNXQXTQTPAJEJL-UHFFFAOYSA-N 0.000 claims description 12
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 11
- 235000019152 folic acid Nutrition 0.000 claims description 11
- 239000011724 folic acid Substances 0.000 claims description 10
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 claims description 9
- 229940014144 folate Drugs 0.000 claims description 9
- 102100024746 Dihydrofolate reductase Human genes 0.000 claims description 7
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 7
- 150000005005 aminopyrimidines Chemical class 0.000 claims description 7
- 108020001096 dihydrofolate reductase Proteins 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 238000009833 condensation Methods 0.000 claims description 5
- 230000005494 condensation Effects 0.000 claims description 5
- 230000005588 protonation Effects 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000000813 microbial effect Effects 0.000 claims description 4
- 230000001613 neoplastic effect Effects 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108010022394 Threonine synthase Proteins 0.000 abstract description 35
- 102000004419 dihydrofolate reductase Human genes 0.000 abstract description 35
- 238000004364 calculation method Methods 0.000 abstract description 24
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 54
- 239000000243 solution Substances 0.000 description 53
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 45
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 43
- 239000007787 solid Substances 0.000 description 40
- 239000000203 mixture Substances 0.000 description 38
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 239000003446 ligand Substances 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- 230000035772 mutation Effects 0.000 description 24
- 102000004190 Enzymes Human genes 0.000 description 22
- 108090000790 Enzymes Proteins 0.000 description 22
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 22
- 238000002360 preparation method Methods 0.000 description 22
- 238000004088 simulation Methods 0.000 description 19
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 18
- 239000011541 reaction mixture Substances 0.000 description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 15
- 239000000758 substrate Substances 0.000 description 15
- 239000000725 suspension Substances 0.000 description 14
- RBVDPKHBXVBBRR-UHFFFAOYSA-N 2-amino-6-(methylamino)-1h-pyrimidin-4-one Chemical compound CNC1=CC(=O)N=C(N)N1 RBVDPKHBXVBBRR-UHFFFAOYSA-N 0.000 description 13
- 230000003993 interaction Effects 0.000 description 12
- 239000006071 cream Substances 0.000 description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- 230000037361 pathway Effects 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 101100332565 Gallus gallus DHFR gene Proteins 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- QCYGXAHYWFUWAU-UHFFFAOYSA-N 2-amino-6,8-dimethylpteridin-4-one Chemical compound NC1=NC(=O)C2=NC(C)=CN(C)C2=N1 QCYGXAHYWFUWAU-UHFFFAOYSA-N 0.000 description 8
- 101000908713 Homo sapiens Dihydrofolate reductase Proteins 0.000 description 8
- FUSUHKVFWTUUBE-UHFFFAOYSA-N buten-2-one Chemical compound CC(=O)C=C FUSUHKVFWTUUBE-UHFFFAOYSA-N 0.000 description 8
- OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 8
- STNJBCKSHOAVAJ-UHFFFAOYSA-N Methacrolein Chemical compound CC(=C)C=O STNJBCKSHOAVAJ-UHFFFAOYSA-N 0.000 description 7
- 150000001768 cations Chemical class 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 229920001429 chelating resin Polymers 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 230000001747 exhibiting effect Effects 0.000 description 6
- 230000002349 favourable effect Effects 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- 125000000623 heterocyclic group Chemical group 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000001953 recrystallisation Methods 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 150000001241 acetals Chemical class 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 238000004807 desolvation Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 230000000717 retained effect Effects 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 239000012608 weak cation exchange resin Substances 0.000 description 5
- WKFOPDFMPKTJIP-UHFFFAOYSA-N 2-amino-6-(propylamino)-1h-pyrimidin-4-one Chemical compound CCCNC1=CC(=O)N=C(N)N1 WKFOPDFMPKTJIP-UHFFFAOYSA-N 0.000 description 4
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000011067 equilibration Methods 0.000 description 4
- 230000036571 hydration Effects 0.000 description 4
- 238000006703 hydration reaction Methods 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- WRWNFZAKUHZONV-UHFFFAOYSA-N methanetricarbaldehyde Chemical compound O=CC(C=O)C=O WRWNFZAKUHZONV-UHFFFAOYSA-N 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 4
- YAYOVHRLVOHYMW-UHFFFAOYSA-N 1h-pyrimidin-6-one;hydrochloride Chemical compound Cl.O=C1C=CN=CN1 YAYOVHRLVOHYMW-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- MLUCVPSAIODCQM-NSCUHMNNSA-N crotonaldehyde Chemical compound C\C=C\C=O MLUCVPSAIODCQM-NSCUHMNNSA-N 0.000 description 3
- MLUCVPSAIODCQM-UHFFFAOYSA-N crotonaldehyde Natural products CC=CC=O MLUCVPSAIODCQM-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000009510 drug design Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 150000002224 folic acids Chemical class 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000005381 potential energy Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- MSTNYGQPCMXVAQ-RYUDHWBXSA-N (6S)-5,6,7,8-tetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-RYUDHWBXSA-N 0.000 description 2
- SZLPRRVCSGZARF-UHFFFAOYSA-N 2-(2-bromoethyl)-2-methyl-1,3-dioxolane Chemical compound BrCCC1(C)OCCO1 SZLPRRVCSGZARF-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- OYJHYDNQKBXDFD-UHFFFAOYSA-N 2-amino-6-(ethylamino)-1h-pyrimidin-4-one Chemical compound CCNC1=CC(=O)N=C(N)N1 OYJHYDNQKBXDFD-UHFFFAOYSA-N 0.000 description 2
- AAUYLLNENYYDTK-UHFFFAOYSA-N 2-amino-8-methylpteridin-4-one Chemical compound CN1C=CN=C2C1=NC(N)=NC2=O AAUYLLNENYYDTK-UHFFFAOYSA-N 0.000 description 2
- ZGHFDIIVVIFNPS-UHFFFAOYSA-N 3-Methyl-3-buten-2-one Chemical compound CC(=C)C(C)=O ZGHFDIIVVIFNPS-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 2
- JRLTTZUODKEYDH-UHFFFAOYSA-N 8-methylquinoline Chemical group C1=CN=C2C(C)=CC=CC2=C1 JRLTTZUODKEYDH-UHFFFAOYSA-N 0.000 description 2
- 244000304337 Cuminum cyminum Species 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 229960003896 aminopterin Drugs 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000005341 cation exchange Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 230000004001 molecular interaction Effects 0.000 description 2
- 238000012587 nuclear overhauser effect experiment Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- CITCTUNIFJOTHI-UHFFFAOYSA-N pteridine-2,4-diamine Chemical group N1=CC=NC2=NC(N)=NC(N)=C21 CITCTUNIFJOTHI-UHFFFAOYSA-N 0.000 description 2
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical compound NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000005460 tetrahydrofolate Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 2
- 229960001082 trimethoprim Drugs 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 238000012784 weak cation exchange Methods 0.000 description 2
- 238000003989 weak cation exchange chromatography Methods 0.000 description 2
- 238000002424 x-ray crystallography Methods 0.000 description 2
- KVJHGPAAOUGYJX-UHFFFAOYSA-N 1,1,3,3-tetraethoxypropane Chemical compound CCOC(OCC)CC(OCC)OCC KVJHGPAAOUGYJX-UHFFFAOYSA-N 0.000 description 1
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 1
- ZJOXWRFJOUWUKX-GOSISDBHSA-N 2-[[4-[(3R)-1-oxo-3,4-dihydroisochromene-3-carbonyl]piperazin-1-yl]methyl]-5,6,7,8-tetrahydro-3H-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical compound C1CCCC2=C1SC1=C2C(=O)NC(CN2CCN(CC2)C([C@@H]2OC(=O)C3=CC=CC=C3C2)=O)=N1 ZJOXWRFJOUWUKX-GOSISDBHSA-N 0.000 description 1
- ZXYWOTINIINELN-UHFFFAOYSA-N 2-amino-6,7,8-trimethylpteridin-4-one Chemical compound CN1C(C)=C(C)N=C2C1=NC(N)=NC2=O ZXYWOTINIINELN-UHFFFAOYSA-N 0.000 description 1
- XSBWKPHDJYFNIF-UHFFFAOYSA-N 2-amino-7,8-dimethylpteridin-4-one Chemical compound CN1C(C)=CN=C2C1=NC(N)=NC2=O XSBWKPHDJYFNIF-UHFFFAOYSA-N 0.000 description 1
- FVWLPLVHCKQEFU-UHFFFAOYSA-N 2-amino-8-ethyl-2,3-dihydropyrido[2,3-d]pyrimidin-4-one Chemical compound O=C1NC(N)N=C2N(CC)C=CC=C21 FVWLPLVHCKQEFU-UHFFFAOYSA-N 0.000 description 1
- NENPVXRQJYZLBI-UHFFFAOYSA-N 2-amino-8-ethyl-6-methyl-2,3-dihydropyrido[2,3-d]pyrimidin-4-one Chemical compound O=C1NC(N)N=C2N(CC)C=C(C)C=C21 NENPVXRQJYZLBI-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- CXYHABCFRUWDBX-UHFFFAOYSA-N 6,7,8-trimethyl-7H-pyrido[2,3-d]pyrimidin-2-amine Chemical compound NC=1N=CC2=C(N=1)N(C(C(=C2)C)C)C CXYHABCFRUWDBX-UHFFFAOYSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical group [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- LHQIJBMDNUYRAM-AWFVSMACSA-N D-erythro-biopterin Chemical compound N1=C(N)NC(=O)C2=NC([C@H](O)[C@H](O)C)=CN=C21 LHQIJBMDNUYRAM-AWFVSMACSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- LHQIJBMDNUYRAM-UHFFFAOYSA-N L-erythro-Biopterin Natural products N1=C(N)NC(=O)C2=NC(C(O)C(O)C)=CN=C21 LHQIJBMDNUYRAM-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- ACWQBUSCFPJUPN-UHFFFAOYSA-N Tiglaldehyde Natural products CC=C(C)C=O ACWQBUSCFPJUPN-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000005263 ab initio calculation Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000000063 antileukemic agent Substances 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical group 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000006961 mixed inhibition Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000006959 non-competitive inhibition Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003195 pteridines Chemical class 0.000 description 1
- 238000004869 quantum mechanical method Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- ACWQBUSCFPJUPN-HWKANZROSA-N trans-2-methyl-2-butenal Chemical compound C\C=C(/C)C=O ACWQBUSCFPJUPN-HWKANZROSA-N 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- This invention relates to a method of designing compounds which bind to the enzyme dihydrofolate reductase (DHFR), novel N5-deazapterin compounds which are useful for inhibiting DHFR and methods of selecting and preparing such compounds using theoretical calculations.
- DHFR dihydrofolate reductase
- DHFR dihydrofolate reductase
- NADPH nicotinamide adenine dinucleotide phosphate
- Analogues of folic acid, particularly inhibitors of DHFR constitute a class of cytotoxic drugs, the antifolates, which are important anticancer, antimalarial, and antibacterial agents.
- inhibitors such as methotrexate and trimethoprim
- Antifolates have been made and tested since 1947 when aminopterin was first made as an analogue of folate and found to be an effective anti-leukemic agent.
- substrate-like compounds containing a pterin-type ring (2-amino-4-oxo- pteridine or deazapteridine), or "inhibitor-like” compounds based on aminopterin/ methotrexate with a 2,4-diamino-pteridine, 2,4-diamino-pyrimidine or related heterocyclic ring.
- DHFR has been a test case for the rational design of new drugs and to that end has been subjected to intensive biochemical characterisation by both experimental and theoretical methods with the aim of understanding substrate and inhibitor binding and species selectivity at the molecular level as the basis of new predictions.
- X-ray structures have been obtained for several dozen DHFRs from different species (including human) in many different binary complexes or ternary complexes with substrate or inhibitors by various research groups. Reported efforts in developing new antifolates using "structure-based" design approach have been of limited success and importantly, X-ray structures have not provided a convincing explanation of the established species-selectivity of binding of the major antibacterial drug trimethoprim.
- DHFR tetrahydrofolate:NADP + oxidoreductase, EC 1.5.1.3
- DHFR tetrahydrofolate:NADP + oxidoreductase
- DHFR catalyses two reactions:
- Folic acid has the following structure:
- novel compounds we have prepared, when protonated, mimic the enzymically-active protonated form of the pterin ring of folate, ie these compounds are based on the enzymic mechanism.
- Folate in solution protonates at N1.
- the novel compounds of the present invention are substituted at the 8-position and in this context, the 8- substitution is believed to freeze the N5-deazapterin into the less stable N8(H)-type tautomeric form, which is calculated to be 12 kcal/mol less stable as shown in
- the present invention provides a method of designing a compound which binds to DHFR, which comprises substituting the position 6 or 8 of a compound having the following structure
- the substitution is alkylation.
- 8- or 6-alkylation freezes these deazapterins into the less stable N8 (H) - or N6 (H) - type tautomeric forms.
- This "activation" by alkylation produces compounds of "quinonoid-type" molecular structure which are necessarily more basic than the normal tautomers, protonating to form cations of the desired structure with effective pK a increase of several units.
- the present invention provides novel compounds of formula (I), pharmaceutically acceptable salts or esters thereof
- R 1 is hydrogen or alkyl optionally substituted by hydroxy, thio or halogen
- R 2 is H, -CHO, -COOH, alkyl, CH(Oalk) 2 , alkyl substituted by hydroxy, thio, halogen, PABA, PABA-Glu; alkenyl, alkynyl;
- R 3 is H, alkyl
- R 4 is alkyl optionally substituted by hydroxy, thio, halogen; alkenyl, alkynyl;
- Glu glutamic acid
- alkyl is methyl, ethyl, propyl or isopropyl; alkenyl is allyl; alkynyl is propargyl; and halogen is fluoro.
- X is preferably chloride or bromide.
- Alkyl includes branched or straight chain alkyl.
- the present invention provides a process of preparing compounds of formula (I), which comprises condensation of an appropriate aminopyrimidme
- R 1 , R 2 , R 3 and R 4 are as hereinbefore defined.
- the present invention provides a method of preparing substituted-N5-deazapterins which comprises condensation of an ⁇ , ⁇ -unsaturated carbonyl compound (IV) with the appropriate aminopyrimidine (II) according to reaction scheme 2:
- R 1 , R 2 , R 3 and R 4 are as hereinbefore defined provided that R 1 , R 2 and R 3 are not all hydrogen.
- the present invention provides a method of selecting a compound having binding affinity to DHFR which method comprises: fa) theoretically determining the relative binding free energy ( ⁇ F bind ) of compounds having potential for binding to DHFR of the following structure and varying substitution patterns:
- X, Y and R are as hereinbefore defined and R is independently selected and one or more R may not be present; by using the free-energy perturbation/molecular dynamics (FEP/MD) method;
- the present invention provides a method of preparing a compound having binding affinity to DHFR which method comprises:
- X, Y and R are as hereinbefore defined and R is independently selected and one or more R may not be present; by using the free-energy perturbation/molecular dynamics (FEP/MD) method;
- the malonaldehyde compound (III) can either be protected (as shown) or unprotected. Even though the unsubstituted form (at C2-position) of the malonaldehyde is shown giving compounds where R 2 is H, the substituted malonaldehydes can also be used in which case R 2 will correspond to the substituent at the C2 -position of the malonaldehyde.
- the general reaction conditions involve placing the pyrimidine in neat carbonyl compound with the carbonyl compound in a molar excess of between 20 and 75. The mixture is heated at about 60oC for a period of several hours. The solution is then acidified with 0.1M HCl and heated further for periods of up to 48 hours. The final product is obtained by the removal of solvent followed by recrystallisation of the residue from ethanol .
- reaction Scheme 2 Initial attempts to prepare some compounds of formula (I) using reaction scheme 1 without bisulfite (ie reaction Scheme 2) proved unsuccessful.
- the preparation of the novel compounds in the presence of bisulfite is generally carried out by treating the appropriate pyrimidine in water with a solution of a molar equivalent of the bis (dialkylacetal) compound or two equivalents of the substituted ⁇ , ⁇ -unsaturated carbonyl compound in the presence of NaHSO 3 in water.
- the pH of the reaction mixture is preferably adjusted to about pH 2-3 and the mixture is stirred for approximately 8 hours under gentle heat ( ⁇ 50°C).
- reaction mixture Examination of the reaction mixture at this stage would indicate whether the pyrimidine had completely reacted with carbonyl and the first stage of the reaction was complete.
- the solution is then acidified to pH 0-1 and heating continued for a further 16 hours approximately, resulting in a final spectrum consistent with deaza-pterin.
- Purification is generally carried out using a column of Amberlite CG-50 weak cation exchange resin.
- the reaction mixture is preferably adjusted to pH 4 and then applied to the column.
- the sample is then eluted with water resulting in a blue-fluorescent band slowly moving down the column to about half column position. At this point a band showing pale-purple fluorescence begins to elute. This band is preferably completely eluted from the column leaving the blue-fluorescent band completely retained.
- 8-R-substitution is a necessary condition for the proposed activation mechanism
- a variety of ring- substituent patterns are also possible, at least in principle, by the addition of methyl or other groups at the 5, 6 and 7 positions of the heterocyclic ring in the case of 8-R-N5-deazapterin (8d) and the 6 and 7 positions of 8-R-pterin (8p).
- the primary 8-methyl compounds (8d and 8p) and their various methyl derivatives are listed in Table I.
- Ligands and abbreviations in the calculations the ligands are protonated at N3.
- the primary "lead” member of the class the simplest derivative 8-methyl-N5-deazapterin, possesses an "intrinsic" capacity to bind to the enzyme DHFR.
- This capacity can be increased or decreased by substitution in the 5-and/or 6- and/or 7- positions, as well as by modification of the 8- substituent itself.
- the FEP/MD method allows the calculation of the effects on the binding constant of varying the. substituents in these positions. The binding constant for a series of compounds can then be ranked from best to worst.
- the free energy change ( ⁇ F bind ) is the sum of the solvation ( ⁇ F solv ) and binding ( ⁇ F bind ) components.
- this desolvation component is non-additive for different numbers and patterns of methyl groups, ie two methyl groups in different combinations of positions will show different desolvation energies resulting from different hydration spheres for the methyl groups or shielding of the 4 -oxygen by a 5- methyl group;
- this binding component [in (3) above] is non- additive for different numbers and patterns of methyl groups.
- the method of selecting a compound having binding affinity to DHFR comprises:
- X, Y and R are as hereinbefore defined and R is independently selected and one or more R may not be present; by using the free-energy perturbation/molecular dynamics (FEP/MD) method;
- the method of preparing a compound having binding affinity to DHFR comprises:
- X, Y and R are as hereinbefore defined and R is independently selected and one or more R may not be present; by using the free-energy perturbation/molecular dynamics (FEP/MD) method;
- the free energy differences are obtained by transforming or "mutating" the potential energy parameters of a ligand A to those of a second ligand B during a molecular dynamics (MD) simulation.
- the relative thermodynamic stabilities of A and B are given by the free energy difference:
- the MD potential energy function, V has the form
- V V bad + V ele + V vdw + V hb (2)
- V bad represents the intramolecular part of the energy, which includes all bond, angle and dihedral terms
- V ele is the electrostatic term arising from nonbonded interactions between atomic charges
- V vdw is the nonbonded van der Waals (vdW) interaction term
- V hb is a hydrogen- bond interaction term.
- the standard AMBER all-atom and united-atom protein force-field parameters were adopted for the DHFR molecule.
- the all-atom model was used for residues within 8A of the ligand centre of mass (cm.), while the united-atom model (in which hydrogens attached to carbon are not represented explicitly) was used for the remainder of the protein.
- ⁇ F bind of A and B can be calculated from the cycle in Scheme 2 using Equation 4.
- the relationship between calculated and experimental values of ⁇ F bind is shown in Scheme 2 and Equation (4).
- the ligands were solvated with boxes of Monte Carlo water using the EDIT module of AMBER. Only those water molecules within 12 ⁇ (in the x, y and z directions) of any solute atom were retained to form a rectangular simulation box.
- the simulations were carried out for the closed, isothermal, isobaric (NTP) ensemble under periodic boundary conditions using a cutoff radius of 8 ⁇ for all nonbonded interactions. As shown in Figure 2, the calculations were divided into four stages. Energy minimization (BORN module of AMBER) was followed by MD equilibration for 7 ps before the mutations were started
- the mutation A ⁇ B was carried out in two stages via an intermediate state A'.
- the intermediate state A' takes on the electrostatic force field of the final state B, but has the same Sampling
- Double-wide sampling can be employed since the Hamiltonian for the perturbation is given in general by V( ⁇ i ) - V( ⁇ i ⁇ ⁇ ). For a given mutation, double-wide sampling yields two values for the free energy change by forming the ensemble averages for both + ⁇ and - ⁇ at ⁇ i , which may be used to test for hysteresis in the calculation. While there are 66 [n(n-1)/2; n compounds] distinct mutations which directly connect any pair of the 12 compounds listed in Table I, not all are independent since the free energy is a path-independent quantity. In theory, the minimum number of FEP simulations that are required to obtain all free energy differences is therefore only 11(n-1).
- free energy changes between two ligands can be estimated by following various pathways that each involve a differing sequence of mutations. For example, to obtain the free energy difference between 678d and 8d one would normally perform the mutation 678d ⁇ 8d directly, however, the desired free energy can also be obtained by performing the sequence of mutations 678d ⁇ 68d ⁇ 8d, where the total free energy is the sum of free energies for the two mutations.
- NADPH.ligand complexes were neutralized by adding counterions and the region within a radius of 16 A of the ligand centre was solvated using EDIT.
- the system was divided into "non-dynamic" atoms whose positions are frozen at the initial X-ray coordinate values and the "dynamic" atoms which are the only ones allowed to move during the various stages of the calculations.
- the dynamic atoms were defined by including all protein residues, counter ions and water within a radius of 16 A from the ligand mass centre. Using these truncation conditions, typically 50 to 60 water molecules were involved in the dynamics. Water molecules and counter ions were restrained from leaving the dynamics region by applying a small harmonic (0.6 kcal/mol/ ⁇ 2 ) radial restoring force.
- the mean structures obtained from these simulations were then energy minimized for the purposes of graphical (using the MidasPlus program) and least-squares superposition analysis.
- ⁇ F bind listed in Table IV have been obtained by calculating the mean free energies over the different pathways in Table III. The resulting estimates of ⁇ F bind relative to 8-methyl-N5-deazapterin (8d) calculated using equation 1 are also listed in Table IV.
- the compounds of formula (I) and the pharmaceutically acceptable salts and esters thereof are useful agents in inhibiting the enzyme DHFR and therefore may be useful in the treatment or prophylaxis of neoplastic or microbial diseases in mammals, including humans when administered in therapeutically effective amounts.
- the present invention provides a method of treatment or prophylaxis of neoplastic or microbial diseases in a host which comprises administering to said host a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof.
- a pharmaceutical formulation of the present invention comprises the active compound together with one or more pharmaceutically acceptable carriers and optionally any other therapeutic ingredient.
- the formulation may conveniently be prepared in unit dosage form and may be prepared according to conventional pharmaceutical techniques. Additionally, the formulations may include one or more accessory ingredients, such as diluents, buffers, flavouring agents, binders, disintegrants, surface active agents, thickeners, lubricants, preservatives and the like.
- Perkin-Elmer LS-50 and Shimadzu spectrometers were used for fluorimetric and UV/vis spectral studies respectively. Buffers used were those of Ellis and
- NADPH was from Boehringer.
- K d determinations Thermodynamic dissociation constants (K d ) were determined by following the quenching of the enzyme fluorescence
- K i value of 0.8 ⁇ M for 6,8-dimethyl-N5-deaza-pterin was determined at pH 6.6.
- K i values were also determined for 6,8-dimethyl-N5-deaza-pterin and 7,8-dimethyl-N5-deaza-pterin by another method of measuring the initial rates at a fixed substrate concentration (50 ⁇ M dihydrofolate or 100 ⁇ M 6,8-dimethylpterin with 100 ⁇ M NADPH) but varying inhibitor concentration (12 -120 ⁇ M).
- the second (incomplete) set of data for dihydrofolate as substrate indicates weaker but still substantial inhibition, as the K m for the 8-methylpterin is much lower (by 2 orders of magnitude) than for the 6,8-dimethylpterin.
- UV/vis and 1 H nmr spectra were recorded using Cary 3 and Bruker AS200 spectrometers. All 1 H nmr spectra were recorded in D 2 O with the spectrum referenced to water at 54.76 or in D 6 -DMSO referenced to ⁇ 2.50. Mass spectra were recorded on an A.E.I MS9 spectrometer at 70eV with DS30 data handling system for high-resolution spectra. Microanalyses were performed by Australian Microanalytical Service, National Analytical Labs, Melbourne, and Australian National University, Canberra.
- HPLC analysis was performed using an LKB system with LKB UV detector (260 nm), Waters fluorescence detector, Waters analysis software (Maxima) and an Activon Exsil SCX 10 ⁇ m analytical column with a flow rate of 2 mL/min.
- the buffer system used was 100 inM NH 4 HCOO/CH 3 CN (80/20) with pH adjusted to 3.3 with formic acid.
- Reverse phase column chromatography Reverse phase (rp) silica column packing material was prepared by the method of Kuhler and Lindsten [J.Am.Chem.Soc. 48 (1983) 3589]. This technique was used for final purification of freeze dried solid. The column used was 25 cm long and 1cm thick and was packed with approximately 2 g of silica. Approximately 40 mg of sample was applied in one experiment and eluted with 0.01M HCl. Under these conditions impurities are retained and deaza pterins are rapidly eluted.
- the pH of the reaction mixture was then adjusted to pH 3 - 4 and a portion of the solution applied to a column of Amberlite CG-50 weak cation exchange resin.
- the sample was eluted with water until a band exhibiting pale purple fluorescence had been completely eluted from the column.
- the sample was then eluted with 0.01M HCl and a colourless band exhibiting strong blue fluorescence collected.
- the UV/vis spectrum of this solution indicated it to be a deaza-pterin. This solution was freeze dried to give 30 mg of white solid 11.
- the pH of the reaction mixture was adjusted to pH 3 - 4 and the solution applied to a column of Amberlite CG-50 weak cation exchange resin.
- the sample was eluted with water until a band exhibiting pale purple fluorescence had been completely eluted from the column.
- the sample was then eluted with 4% formic acid and a colourless band exhibiting strong blue fluorescence collected.
- the UV/vis spectrum of this solution indicated it to be deaza-pterin. This solution was freeze dried to give (30mg) of 13.
- the pH of the reaction mixture was adjusted to pH 3 - 4 and the solution applied to a column of Amberlite CG-50 weak cation exchange resin.
- the sample was eluted with a weak bisulfite solution until a band exhibiting pale purple fluorescence had been completely eluted from the column.
- the sample was then eluted with 0.01M HCl and a colourless band exhibiting strong blue fluorescence collected.
- the UV/vis spectrum of this solution indicated it to be deaza-pterin. This solution was freeze dried to give (100mg) of 14. uv: pH 2 ⁇ max 358 , 278 , 214.
- reaction mixture was passed through a wcx column eluting with water then 0.01M HCl.
- a clear colourless blue-fluorescent fraction was collected ( ⁇ 200 mL) and freeze dried to give 60 mg of pale yellow solid (30% yield).
- This solid was dissolved in water and passed through an rp silica column eluting with water.
- a clear colourless blue-fluorescent fraction was collected which was acidified and freeze dried to give 50 mg of white solid.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Procédé permettant de développer des composés qui se lient à l'enzyme de dihydrofolate réductase (DHFR), composés de N5-désazaptérine de la formule (I) utilisés pour inhiber la DHFR et procédés de sélection et de préparation de tels composés à l'aide de calculs théoriques. Composés de la formule (I), leurs sels ou esters pharmaceutiquement acceptables, formule dans laquelle R1 représente hydrogène ou alkyle éventuellement substitué par hydroxy, thio ou halogène; R2 représente H, -CHO, -COOH, alkyle, CH(Oalk)¿2?, alkyle substitué par hydroxy, thio, halogène, PABA, PABA-Glu, alcényle, alcynyle; R?3¿ représente H, alkyle; R4 représente alkyle éventuellement substitué par hydroxy, thio, halogène, alcényle, alcynyle; X- représente halogène.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPL165192 | 1992-04-01 | ||
AUPL1651 | 1992-04-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993020075A1 true WO1993020075A1 (fr) | 1993-10-14 |
Family
ID=3776067
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU1993/000138 WO1993020075A1 (fr) | 1992-04-01 | 1993-03-31 | N5-desazapterines substituees en position 8, utilisees comme antifolates |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1993020075A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6622094B2 (en) * | 1996-02-15 | 2003-09-16 | The Trustees Of Columbia University In The City Of New York | Method for determining relative energies of two or more different molecules |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4237289A (en) * | 1977-07-20 | 1980-12-02 | Burroughs Wellcome Co. | 2,7-Diamino-8-methyl-5-substituted pyrido{2,3-d}pyrimidin-6-ones |
AU5510886A (en) * | 1985-03-08 | 1986-09-24 | Trustees Of Princeton University, The | Pyrido (2,3-d) pyrimidin derivatives |
AU7426287A (en) * | 1986-06-30 | 1988-01-07 | Trustees Of Princeton University, The | 4(3h)-oxo-5,6,7,8-tetrahydropyrido-(2,3-d)pyrimidine derivatives |
AU7417591A (en) * | 1990-04-12 | 1991-10-17 | Health Research Inc. | Difluoroglutamic acid conjugates with folates and anti- folates for the treatment of neoplastic diseases |
-
1993
- 1993-03-31 WO PCT/AU1993/000138 patent/WO1993020075A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4237289A (en) * | 1977-07-20 | 1980-12-02 | Burroughs Wellcome Co. | 2,7-Diamino-8-methyl-5-substituted pyrido{2,3-d}pyrimidin-6-ones |
AU5510886A (en) * | 1985-03-08 | 1986-09-24 | Trustees Of Princeton University, The | Pyrido (2,3-d) pyrimidin derivatives |
AU7426287A (en) * | 1986-06-30 | 1988-01-07 | Trustees Of Princeton University, The | 4(3h)-oxo-5,6,7,8-tetrahydropyrido-(2,3-d)pyrimidine derivatives |
AU7417591A (en) * | 1990-04-12 | 1991-10-17 | Health Research Inc. | Difluoroglutamic acid conjugates with folates and anti- folates for the treatment of neoplastic diseases |
Non-Patent Citations (2)
Title |
---|
THE JOURNAL OF ORGANIC CHEMISTRY, Vol. 47, No. 5, issued 26 February 1982 (Birmingham, Alabama), C. TEMPLE, R. ELLIOT AND J. MONTGOMERY, "Pyrido (2,3-d) Pyrimidines. Synthesis of the 5-Deaza Analogues of Aminopterin, Methotrexate, Folic Acid, and N10-Methylfolic Acid", pages 761-764. * |
THE JOURNAL OF ORGANIC CHEMISTRY, Volume 53, No. 17, issued 19 august 1988 (Spain), J. ANGUIANO et al., "AM1 Study of the Protonation of Pteridine-Related Tetraazan Aphthalenes", pages 3900-3903. * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6622094B2 (en) * | 1996-02-15 | 2003-09-16 | The Trustees Of Columbia University In The City Of New York | Method for determining relative energies of two or more different molecules |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020210312B2 (en) | Certain chemical entities, compositions, and methods | |
AU2004255934B2 (en) | Isethionate salt of a selective CDK4 inhibitor | |
DeGraw et al. | Synthesis and antifolate properties of 5, 10-ethano-5, 10-dideazaaminopterin | |
EP2396325B1 (fr) | Dérivés d'azaindoles comme inhibiteurs des protéines kinases abl et src | |
ES2377610B1 (es) | Preparación de compuestos pirido[2,3-d]pirimidin-7(8h)-ona sustituidos. | |
CZ283281B6 (cs) | Způsob přípravy v poloze 5 substituovaných pyrrolo(2,3-d)pyrimidinů | |
Piper et al. | Studies on analogs of classical antifolates bearing the naphthoyl group in place of benzoyl in the side chain | |
EP1809292B1 (fr) | Derives de pyrimidine condenses comme inhibiteurs d'enzymes dependant d'acide folique | |
Hynes et al. | Chemistry and antitumor evaluation of selected classical 2, 4-diaminoquinazoline analogs of folic acid | |
Mohebbi et al. | Synthesis, dihydrofolate reductase inhibition, anti-proliferative testing, and saturation transfer difference 1h-nmr study of some new 2-substituted-4, 6-diaminopyrimidine derivatives | |
Kempton et al. | Lysine and ornithine analogs of methotrexate as inhibitors of dihydrofolate reductase | |
Griffin et al. | Structural studies on bioactive compounds. 8. Synthesis, crystal structure and biological properties of a new series of 2, 4-diamino-5-aryl-6-ethylpyrimidine dihydrofolate reductase inhibitors with in vivo activity against a methotrexate-resistant tumor cell line | |
ES2309567T3 (es) | Derivados de imidazopiridinas como inhibidores de no-sintasa inducible. | |
HUP0302262A2 (hu) | Fémes központi atomokon alapuló nitrogén-(II)-oxid-donorok | |
WO1993020075A1 (fr) | N5-desazapterines substituees en position 8, utilisees comme antifolates | |
Hynes et al. | Synthesis of 5-chloro-5, 8-dideaza analogs of folic acid and aminopterin targeted for colon adenocarcinoma | |
CN114945574B (zh) | Btk抑制剂 | |
CN113004305B (zh) | 大环化合物及其制备方法和用途 | |
Dutta et al. | Synthesis and biological activities of some N6-(nitro-and-aminobenzyl) adenosines | |
Makowski et al. | Quinazoline antifolate thymidylate synthase inhibitors: Replacement of glutamic acid by aminophosphonic acids | |
KR20190067247A (ko) | 피리도[3,4-d]피리미딘 유도체 또는 그 용매화물의 결정 | |
Gangjee et al. | Synthesis of substituted tetrahydropyrimido‐[4, 5‐b][1, 7] naphthyridines as potential antitumor agents | |
유희원 et al. | The Reaction of 6, 7-Dichloro-5, 8-quinoxalinedione with Aromatic and Aliphatic Dinucleophiles and Molecular Modeling Study of Their Intercalation Complexes | |
WO1990004593A1 (fr) | Desamino-aminopterine et desamino-methotrexate | |
WO1993004051A1 (fr) | Analogues 2-aza-2-desamino de l'acide 5,8-dideazafolique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
122 | Ep: pct application non-entry in european phase |